News
Hemab Therapeutics ApS raised $135 million in a series B funding round to continue its broad effort to build a company focused on developing prophylactic therapies for neglected bleeding and ...
COPENHAGEN, Denmark and BOSTON, July 22, 2021 /PRNewswire/ -- Novo Holdings, a leading international life science investor, today announces that i ...
COPENHAGEN, Denmark and BOSTON, July 22, 2021 /PRNewswire/ -- Hemab ApS ("Hemab"), a biotech company developing next generation therapeutics for serious underserved bleeding and thrombosis ...
COPENHAGEN, Denmark, Dec. 14, 2020 /PRNewswire/ -- Novo Seeds, the early stage investment and company creation team of Novo Holdings, announced today that it has invested in a new portfolio ...
COPENHAGEN, Denmark and BOSTON, Sept. 21, 2021 /PRNewswire/ -- Hemab ApS ("Hemab"), a biotech company developing next generation therapeutics for serious underserved bleeding and thrombosis ...
Copenhagen, Denmark and Boston, US – 22 July 2021 – Novo Holdings, a leading international life science investor, today announces that it has co-led alongside HealthCap and RA Capital Management a US$ ...
Copenhagen, Denmark and Boston, US – 22 July 2021 – Hemab ApS (“Hemab”), a biotech company developing next generation therapeutics for serious underserved bleeding and thrombosis disorders, today ...
COPENHAGEN, Denmark and BOSTON, Sept. 21, 2021 /PRNewswire/ -- Hemab ApS ("Hemab"), a biotech company developing next generation therapeutics for serious underserved bleeding and thrombosis ...
nasdaq 100. euro stoxx 50. ftse-100 ...
COPENHAGEN, Denmark and BOSTON, Sept. 21, 2021 /PRNewswire/ -- Hemab ApS (Hemab), a biotech company developing next generation therapeutics for se. Tuesday, 02 January 2024 12:17 GMT.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results